http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Jong Jin Hyun ),( Jae Min Lee ),( Seung Young Kim ),( Sang Jun Suh ),( Sung Woo Jung ),( Young Kul Jung ),( Ja Seol Koo ),( Hyung Joon Yim ),( Hong Sik Lee ),( Sang Woo Lee ),( Chang Duck Kim ) 대한내과학회 2014 대한내과학회 추계학술발표논문집 Vol.2014 No.1
Background: Currently available medications to dissolve gallbladder stones are ursodeoxycholic acid(UDCA) or a combination of chenodeoxycholic acid(CDCA) and UDCA. In the previous studies, dissolution effi cacy had been compared after excluding patients with stones evident on plain abdominal X-ray but CT scan was not routinely performed to evaluate the presence of calcifi cation. This study was conducted to compare the dissolution effi cacy of UDCA alone or a combination of CDCA and UCDA(CNU) according to stone density on CT scan. Methods: Among a total of 393 gallbladder stone patients who presented to the outpatient department of Korea University Ansan Hospital from December 2010 to March 2014, 124 patients underwent dissolution therapy with either CNU(n=61) or UDCA(n=63). Of these patients, 53 were excluded because of follow-up loss (n=37) or symptom development necessitating cholecystectomy(n=6). In the end, 71 patients (CNU group = 42, UDCA group = 29) were included for analysis. Dissolution was considered effective if the largest stone size diameter showed decrease of >50% or completely dissolved. Stone density on CT scan was divided into four groups: hypodense,isodense, hyperdense, and calcifi ed. Results: The baseline age (49.40±14.85 years vs. 53.59±19.90 years), treatment duration (183.07±16.02 days vs. 180.48±16.10 days), and pre-treatment stone size (8.74±4.25mm vs. 9.20±4.50mm) were not different between the CNU group and UDCA group. Effective dissolution was observed in 26.2% (11/42) and 48.3% (14/29) of patients after CNU and UDCA treatment, respectively (p=0.055). When only those with stones that were hypodense or isodense on CT scan were analyzed, the effective dissolution rate rose to 57.1% (8/14) and 75% (9/12) with CNU and UDCA treatment, respectively (p=0.429). Conclusions: Patients with gallbladder stones that were hypodense or isodense showed much better dissolution effi cacy. Therefore, CT scan should be performed prior to medication therapy if stone dissolution is intended.
Song, Yoseb,Lee, Jin Soo,Shin, Jongoh,Lee, Gyu Min,Jin, Sangrak,Kang, Seulgi,Lee, Jung-Kul,Kim, Dong Rip,Lee, Eun Yeol,Kim, Sun Chang,Cho, Suhyung,Kim, Donghyuk,Cho, Byung-Kwan National Academy of Sciences 2020 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF Vol.117 No.13
<P><B>Significance</B></P><P>Despite sharing the first four reactions, coutilization of the Wood–Ljungdahl pathway (WLP) with the glycine synthase-reductase pathway (GSRP) and reductive glycine pathway (RGP) to fix C1 compounds has remained unknown. In this study, using <I>Clostridium drakei</I>, we elucidated the role of the GSRP and RGP in the presence of the WLP, via a genome-scale metabolic model, RNA-seq, <SUP>13</SUP>C isotope-based metabolite-tracing experiments, biochemical assays, and heterologous expression. Overall, the data suggested the pathways are functional under autotrophic conditions. Along with the WLP, GSRP and RGP convert CO<SUB>2</SUB> to glycine and then to acetyl-phosphate and serine, which then obtain ATP by producing acetate and operate with limited reducing power. This is a unique coutilization of the pathways under autotrophic conditions in acetogens.</P><P>Among CO<SUB>2</SUB>-fixing metabolic pathways in nature, the linear Wood–Ljungdahl pathway (WLP) in phylogenetically diverse acetate-forming acetogens comprises the most energetically efficient pathway, requires the least number of reactions, and converts CO<SUB>2</SUB> to formate and then into acetyl-CoA. Despite two genes encoding glycine synthase being well-conserved in WLP gene clusters, the functional role of glycine synthase under autotrophic growth conditions has remained uncertain. Here, using the reconstructed genome-scale metabolic model <I>i</I>SL771 based on the completed genome sequence, transcriptomics, <SUP>13</SUP>C isotope-based metabolite-tracing experiments, biochemical assays, and heterologous expression of the pathway in another acetogen, we discovered that the WLP and the glycine synthase pathway are functionally interconnected to fix CO<SUB>2</SUB>, subsequently converting CO<SUB>2</SUB> into acetyl-CoA, acetyl-phosphate, and serine. Moreover, the functional cooperation of the pathways enhances CO<SUB>2</SUB> consumption and cellular growth rates via bypassing reducing power required reactions for cellular metabolism during autotrophic growth of acetogens.</P>
NAFLD Is Associated with High Prevalence and High Recurrence Rate in Patients with Breast Cancer
( Young-sun Lee ),( Sung Won Chang ),( Ha Seok Lee ),( Haein Bak ),( Sehwa Kim ),( Min-jin Lee ),( Chan Uk Lee ),( Young Kul Jung ),( Ji Hoon Kim ),( Yeon Seok Seo ),( Hyung Joon Yim ),( Jong Eun Yeon 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Breast cancer is most common cancer in women worldwide. The incidence of breast cancer is correlated with metabolic component including diabetes, hypertension, and obesity. Likewise breast cancer, metabolic components are important risk factors for development of NAFLD. In this study, we analyzed the prevalence of NAFLD in patients with breast cancer and the effect of NAFLD on the prognosis of breast cancer. Methods: Patients with breast cancer were enrolled from January 2007 to June 2017. Patients who had other chronic liver were excluded. Hepatic steatosis was evaluated by non-enhanced CT scan. We diagnosed NAFLD when the mean attenuation of the liver is lower than 40 HU or 10 HU lower than that of the spleen. 123 healthy controls who took non-enhanced CT scan were also analyzed. Results: Total 1587 patients were enrolled from January 2007 to June 2017. The prevalence of NAFLD in patients with breast cancer was 15.8% (251/1587) and it was significantly higher comparing with healthy control (8.9%, 11/123)(P=0.036). After propensity score matching, the difference of NAFLD prevalence was still significant between control group (8.9%, 11/123) and breast cancer patients (17.9%, 22/123) (P=0.040). In breast cancer patients, overall survival did not showed significant difference between NAFLD group and non-NAFLD group (P=0.304) (Figure A). However, recurrence-free survival was significantly higher in patients without NAFLD comparing with those with NAFLD (P=0.009) (Figure B). Among breast cancer patients received endocrine treatment, NAFLD group showed higher cumulative incidence of significant liver injury comparing with non-NAFLD group (P<0.001). Conclusions: The prevalence of NAFLD in patients with breast cancer is significantly high compared to healthy control group. Moreover, breast cancer patients with NAFLD showed poor prognosis in terms of recurrence. Therefore, diagnostic evaluation to determine whether or not NAFLD is present would be important in managing patients with breast cancer.
( Young-sun Lee ),( Ha Seok Lee ),( Ji Hoon Kim ),( Sung Won Chang ),( Myung Han Hyun ),( Haein Bak ),( Sehwa Kim ),( Min-jin Lee ),( Chan Uk Lee ),( Young Kul Jung ),( Yeon Seok Seo ),( Hyung Joon Yi 대한내과학회 2021 The Korean Journal of Internal Medicine Vol.36 No.1
Background/Aims: To prevent the perinatal transmission of hepatitis B virus (HBV) from mother to child, administration of an antiviral agent during pregnancy has been attempted in women who are either hepatitis B e antigen positive or have a high viral load. In this systematic review and meta-analysis with randomized controlled trials, we analyzed the efficacy and safety of tenofovir disoproxil fumarate (TDF) in preventing the perinatal transmission of HBV in pregnant women who have high HBV DNA titers. Methods: Multiple comprehensive databases (PubMed, EMBASE, and Cochrane databases) were searched for studies evaluating the efficacy of TDF for the prevention of perinatal transmission of HBV. Results: Two studies (one open label study and one double blind study) were included and analyzed. Intention-to-treat analysis (527 pregnancies) showed that the preventive effect of TDF was not significant (odds ratio [OR], 0.53; 95% confidence interval [CI], 0.13 to 2.17; p = 0.38, I<sup>2</sup> = 81%). However, the per-protocol analysis showed that TDF significantly reduced perinatal transmission (OR, 0.10; 95% CI, 0.01 to 0.77; p = 0.03, I<sup>2</sup> = 0%). There was no significant difference between the TDF group and the control group with respect to maternal and fetal safety outcomes. Conclusions: In pregnant women who have high HBV DNA titers, TDF can reduce the perinatal transmission from mother to child without significant adverse events.
( Young-sun Lee ),( Sung Won Chang ),( Ha Seok Lee ),( Haein Bak ),( Sehwa Kim ),( Min-jin Lee ),( Chan Uk Lee ),( Young Kul Jung ),( Ji Hoon Kim ),( Yeon Seok Seo ),( Hyung Joon Yim ),( Jong Eun Yeon 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: AJCC staging is the most commonly used staging system in most solid tumors, and recent AASLD hepatocellular carcinoma (HCC) guideline also endorsed this AJCC staging system based on status of tumor, node, and metastasis. Recently, 8th edition of AJCC staging system was released in December 2016. This study aimed to compare prediction of survival in HCC patients between 7th AJCC staging system and 8th AJCC staging system. Methods: From 2004 to 2013, 2211 newly diagnosed HCC patients were consecutively enrolled in three Korea University medical centers and the medical records of patients were retrospectively reviewed. Each patients were classified following both of 7th AJCC staging system and 8th AJCC staging system. Results: Chronic hepatitis B (1523, 68.9%) was main attributable factor in development of HCC, followed by chronic hepatitis C (256, 11.6 %) and alcohol consumption (241, 10.9%). 1514 patients (68.5%) died during study period and median overall survival (OS) was 24.7 months. According to 7th AJCC staging system, 894 (40.4%) patients were included into stage I; 459 patients (20.8%) into stage II; 180 patients (8.1%) into stage IIIa; 354 patients (16.0%) into stage IIIb; 3 patients (0.1%) into stage IIIc; 119 patients (5.4%) into stage IVa; and 202 patients (9.1%) into stage IVb. According to 8th AJCC staging system, 400 (18.1%) patients were categorized into stage IA; 498 patients (22.5%) into stage IB; 442 patients (20.2%) into stage II; 193 patients (8.7%) into stage IIIa; 357 patients (16.1%) into stage IIIb; 119 patients (5.4%) into stage IVa; and 202 patients (9.1%) into stage IVb. Both 7th staging system and 8th staging system show distinct survival outcomes according to each stage. Although 7th AJCC staging system significantly well predicted 1 year of survival than 8th AJCC staging system (AUROC; 0.796 vs 0.784, P=0.013), AUROCs of 3 year and 5 year were similar in 7th and 8th AJCC staging system (0.754 vs 0.752 in 3 year, P=0.601; 0.744 vs 0.742 in 5 year, P=0.643). Conclusions: Both 7th and 8th AJCC staging system show distinct survival outcome according to each stage. Moreover, both 7th and 8th AJCC staging system are similar in prediction of survival outcomes.
담체가 Re-188-Hydroxyethylidene Diphosphonate의 표지와 생체내분포에 미치는 영향
장영수,이상은,이승진,이명철,이동수,정준기,정재민,조정혁,김보광,김인걸 대한핵의학회 2000 핵의학 분자영상 Vol.34 No.4
Purpose: Re-188-Hydroxyethylidene diphosphonate (HEDP) is a new cost-effective agent for systemic radioisotope therapy of metastatic bone pain. We investigated the influence of carrier for labeling and biodistribution of Re-188-HEDP using HEDP kit with or without carrier (KReO4). Materials and Methods: The kits (HEDP 15 mg, gentisic acid 4 mg and SnCl2.2H2O 4.5 mg) with or without carrier (KReO4 0.1 mg) were labeled with Re-188 solution, made available from an in-house generator by boiling for 15 min. We compared the labeling efficiency and stability of carrier-added and carrier-free preparations of Re-188-HEDP. Biodistribution and imaging studies of each preparation were performed in ICR mice (1.85∼3.7 MBq/0.1 ml) and SD rats (74.1∼85.2 MBq/0.5 ml). Results: The carrier-added preparation showed high labeling efficiency (95% at pH 5) and high stability in serum (88%, 3 hr). However, the carrier-free preparation showed low labeling efficiency (59% at pH 5) and low stability (43%, 3 hr). The carrier-added preration showed high uptake in bone and low uptake in stomach and kidneys. However, the carrier-free preparation showed lower uptake in bone and higher uptake in both stomach and kidneys, which is supposed to be due to released perrhenate. The carrier-added preparation also showed better images with higher skeletal accumulation, lower uptake in other organs and lower soft tissue uptake than the carrier-free preparation. Conclusion: The results of these studies clearly demonstrate that addition of carrier perrhenate is required for high labeling efficiency, stability, bone uptake and good image quality of Re-188-HEDP. (Korean J Nucl Med 2000;34:344-52)